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The Clinical Measures Associated with C-peptide Decline in 
Patients with Type 1 Diabetes over 15 Years
This study was done to characterize the natural course of C-peptide levels in patients with 
type 1 diabetes and identify distinguishing characters among patients with lower rates of 
C-peptide decline. A sample of 95 children with type 1 diabetes was analyzed to 
retrospectively track serum levels of C-peptide, HbA1c, weight, BMI, and diabetic 
complications for the 15 yr after diagnosis. The clinical characteristics were compared 
between the patients with low and high C-peptide levels, respectively. The average 
C-peptide level among all patients was significantly reduced five years after diagnosis 
(P < 0.001). The incidence of diabetic ketoacidosis was significantly lower among the 
patients with high levels of C-peptide (P = 0.038). The body weight and BMI standard 
deviation scores (SDS) 15 yr after diagnosis were significantly higher among the patients 
with low C-peptide levels (weight SDS, P = 0.012; BMI SDS, P = 0.044). In conclusion, 
C-peptide level was significantly decreased after 5 yr from diagnosis. Type 1 diabetes 
patients whose beta-cell functions were preserved might have low incidence of diabetic 
ketoacidosis. The declines of C-peptide level after diagnosis in type 1 diabetes may be 
associated with changes of body weight and BMI.
Key Words: Diabetes Mellitus, Type 1; C-Peptide; Body Weight; Body Mass Index; 
Diabetic Ketoacidosis
Tae Ho Lee,1 Ah Reum Kwon,1  
Ye Jin Kim,1 Hyun Wook Chae,1  
Ho Seong Kim,1 and Duk Hee Kim2
1Department of Pediatrics, Yonsei University College 
of Medicine, Seoul; 2Sowha Children’s Hospital, 
Seoul, Korea
Received: 13 April 2013
Accepted: 8 July 2013
Address for Correspondence:
Hyun Wook Chae, MD
Department of Pediatrics, Gangnam Severance Hospital,  
211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea
Tel: +82.2-2019-3355, Fax: +82.2-3461-9473
E-mail: hopechae@yuhs.ac
http://dx.doi.org/10.3346/jkms.2013.28.9.1340 • J Korean Med Sci 2013; 28: 1340-1344
ORIGINAL ARTICLE
Endocrinology, Nutrition & Metabolism
INTRODUCTION
For many years, C-peptide was thought to be merely a derivate 
of insulin synthesis. C-peptide is co-secreted with insulin, but 
the half-life of C-peptide is about 10 times longer than that of 
insulin (1). Hence, serum C-peptide is used as a substitute mark-
er for monitoring endogenous insulin production (2, 3).
 In the past two decades, numerous studies demonstrated 
that C-peptide functions independently of insulin and controls 
the vascularity of many vital organs (4-7). In a long-term clini-
cal observation, patients with type 1 diabetes who maintained 
minimal levels of C-peptide were less inclined to develop mi-
crovascular complications of the eyes, peripheral nerves, and 
kidneys compared with patients whose beta-cell functions were 
stopped completely (8). Studies of humans and animals show 
that infusions of synthetic C-peptide slow the progressive dam-
age to the kidneys and peripheral nerves caused by type 1 dia-
betes (6, 7).
 The preservation of C-peptide could be an important factor 
in the management of type 1 diabetes, but longitudinal C-pep-
tide studies are currently sparse. During the first few years fol-
lowing diagnosis, the pattern of C-peptide decline is highly vari-
able and is associated with several factors including the age at 
diagnosis, the degree of metabolic control, and immune status 
of the patient (8, 9). Much longer periods of observation, how-
ever, are necessary to fully understand the role of C-peptide in 
the management of type 1 diabetes.
 We retrospectively investigated patients with type 1 diabetes 
who managed their disease for over 15 yr, and we examined the 
correlations between C-peptide levels and other clinical para-
meters. In addition, we compared the clinical parameters be-
tween patients with low C-peptide levels and those whose C-
peptide levels were relatively preserved over the 15 yr following 
diagnosis. 
MATERIALS AND METHODS
We identified 95 patients (56 [59%] female and 39 [41%] male) 
who were diagnosed with type 1 diabetes as children and were 
followed for at least 15 yr after their diagnosis by researchers at 
the Childhood Diabetes Clinic of Severance Children’s Hospi-
tal. Type 1 diabetes was defined by glucose level of more than 
200 mg/dL, clinical characteristics, antibody positivity and de-
creased C-peptide level through the oral glucose tolerance test 
or the standard mixed meal tolerance test at initial visit. The ages 
of the patients at the time of diagnosis ranged from 1 to 16 yr. 
Most of the patients were treated with a conventional insulin 
regimen; the number of subjects receiving intensive insulin treat-
ment 10 and 15 yr after their diagnosis was five and 35, respec-
tively. We excluded patients with slowly progressive type 1 dia-
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betes who were initially misdiagnosed as having type 2 diabe-
tes, respectively.
 We recorded the patients’ sex, onset age, and family history. 
The family history included the history of all types of diabetes in 
any third-degree relatives. We collected data for serum fasting 
C-peptide levels at the time of diagnosis and 1, 3, 5, 10, and 15 
yr after diagnosis. We used fasting C-peptide levels instead of 
postprandial or stimulated levels, because fasting levels were 
measured for the majority of the patients. The serum C-peptide 
levels were assessed by the radioimmunoassay technique using 
commercial kits (Daiichi, Tokyo, Japan). We also collected data 
for parameters such as HbA1c, triacylglycerol (TG), total cho-
lesterol, high-density lipoprotein (HDL), and daily insulin dose. 
Our data included the incidences of diabetic complications such 
as diabetic retinopathy, peripheral neuropathy, albuminuria, 
and diabetic ketoacidosis (DKA). Diabetic retinopathy was di-
agnosed by an ophthalmologist, and peripheral neuropathy 
was confirmed by a neurologist with electromyography and 
nerve conduction study. Albuminuria was confirmed when the 
albumin excretion in 24-hr urine was more than 30 mg in re-
peated tests. DKA was diagnosed when glucose ≥ 250 mg/dL, 
pH ≤ 7.30, HCO3- ≤ 18 mEq/L, and the patient was positive for 
ketonuria. The weight and body mass index (BMI) standard de-
viation scores (SDS) of the patients were calculated by the Z-
scores of the 2007 Korean National Growth Chart.
 We analysed the declines in fasting C-peptide level and the 
clinical characteristics between the patients with low C-peptide 
levels (< 0.05 nM/L, Group A) and those with relatively pre-
served C-peptide levels (≥ 0.05 nM/L, Group B); we used the 
serum C-peptide levels 15 yr after diagnosis to assign the pa-
tients to the groups.
 We analysed the data using the SAS program (version 9.1; 
SAS Institute, Cary, NC, USA). We used a linear mixed model to 
verify the demographic trends of the continuous variables over 
time respectively between the two groups of patients. We used 
chi-square tests or Fisher’s exact tests to analyse the categorical 
data of the two groups. Statistical significance was determined 
as P < 0.05. 
Ethics statement
This study was approved by the institutional review board of 
Yonsei University Severance Hospital (IRB number 4-2012-0721). 
Written informed consent was exempted by the board. 
RESULTS
Among the 95 patients, family history of diabetes was present in 
14 (15%). In the study, the average age of onset of type 1 diabe-
tes among the patients was 7.7 yr. The average initial fasting C-
peptide level was 0.187 nM/L. The average fasting C-peptide 
level was slightly higher than the initial level one year after di-
agnosis, and it slowly decreased thereafter. The average C-pep-
tide level was significantly reduced from the initial level five 
years after diagnosis (P < 0.001, Table 1). When we compared 
the decline in the C-peptide levels between the patients in Group 
A (n = 76) and those in Group B (n = 19), we found that the dif-
ference in C-peptide levels between the two groups was signifi-
cant 10 yr after diagnosis (P = 0.015). The C-peptide levels de-
creased rapidly five years after diagnosis in Group A, compared 
with relatively stable C-peptide levels in Group B during the 
same period (Fig. 1). 
 We found no significant differences between the groups in 
the age at diagnosis, sex, family history, daily required insulin 
doses per weight, and insulin treatment regimen. We found no 
significant differences between the groups in their average lev-
els of HbA1c, TG, total cholesterol, and HDL over the 15 yr fol-
lowing diagnosis (Table 1).
 DKA had a significantly lower incidence rate in Group B than 
in Group A (P = 0.038, Table 2). The incidence rates of diabetic 
retinopathy, peripheral neuropathy, and albuminuria were not 
significant different between the two groups. We found no sig-
nificant correlation between any of the complications and on-
set age, sex, or family history.
 We found that onset age, sex, family history, mean HbA1c, 
lipid profiles, and incidences of complications, except for DKA, 
were not correlated with the decline of C-peptide. Although the 
weight SDS (-0.38 ± 1.22) and BMI SDS (-0.83 ± 1.38) were ini-
Table 1. Average values of type 1 diabetes parameters during serial follow-up over 15 yr
Parameters 0 yr 1 yr 3 yr 5 yr 10 yr 15 yr
Number of patients 95 70 73 63 94 95
Age of onset (yr) 7.8 ± 4.1 8.4 ± 4.0 10.5 ± 3.8 12.6 ± 3.8 17.7 ± 4.1 22.8 ± 4.1
C-peptide (nM/L) 0.187 ± 0.093 0.222 ± 0.127 0.190 ± 0.085 0.173 ± 0.062 0.096 ± 0.076* 0.029 ± 0.096*
HbA1c (%) 14.0 ± 4.4 10.2 ± 3.9* 10.4 ± 3.3* 9.8 ± 2.7* 9.3 ± 2.2* 8.7 ± 2.1*
Triglyceride (mM/L) 2.73 ± 4.19 0.87 ± 0.54† 1.10 ± 0.9† 1.30 ± 1.53† 1.02 ± 0.57† 1.03 ± 0.68†
Total cholesterol (mM/L) 5.15 ± 2.25 4.27 ± 0.83 4.42 ± 0.78 4.47 ± 0.96 4.47 ± 0.78 4.55 ± 0.88
HDL (mM/L) 1.16 ± 0.47 1.32 ± 0.36† 1.45 ± 0.39† 1.40 ± 0.36* 1.63 ± 0.36* 1.60 ± 0.34*
Insulin dose (units/kg ∙ day) 0.8 ± 0.3 0.7 ± 0.3 0.9 ± 0.3 1.0 ± 0.3† 1.0 ± 0.3† 0.9 ± 0.2
Weight SDS -0.38 ± 1.22 0.00 ± 1.10† -0.03 ± 1.02† 0.17 ± 0.93* 0.09 ± 1.04† 0.21 ± 1.13*
BMI SDS -0.83 ± 1.38 -0.15 ± 1.01* -0.07 ± 0.92* 0.07 ± 0.79* 0.10 ± 0.96* 0.23 ± 1.05*
Data were analysed and compared from baseline with the use of a linear mixed model. *P < 0.001, †P < 0.05. Data are represented as mean ± SD. HbA1c, glycated Hemo-
globin A1c; HDL, high-density lipoprotein; SDS, standard deviation score; BMI, body mass index.
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Fig. 1. Average fasting C-peptide levels of each of group A and B at the time of diag-
nosis and during serial follow-up over 15 yr. *P = 0.015 between groups A and B at 
the 15th year after diagnosis from a linear mixed model. Data are represented as 
mean ± SE. Black circle = group A, C-peptide level at 15th year < 0.05 nM/L; white 
circle = group B, C-peptide level at 15th year ≥ 0.05 nM/L.
Fig. 2. Average body weight and BMI during follow-up period. (A) Body weight SDS with time progression in each of the two groups. *P = 0.012 between groups A and B at the 
15th year after diagnosis from a linear mixed model. (B) BMI SDS with time progression in each of the two groups. †P = 0.044 between group A and B at the 15th year after 
diagnosis from a linear mixed model. Data are represented as mean ± SE. Black circle = group A, C-peptide level at 15th year < 0.05 nM/L; white circle = group B, C-peptide 
level at 15th year ≥ 0.05 nM/L.
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Table 2. The incidences of type 1 diabetes complications between least and pre-
served C-peptide group
Complication Total (n = 95) Group A (n = 76) Group B (n = 19) P
Diabetic retinopathy 19 (20.0%) 16 (21.1%) 3 (15.8%) 0.756
Peripheral Neuropathy 13 (13.7%) 12 (15.8%) 1 (5.3%) 0.454
Albuminuria 18 (18.9%) 14 (18.4%) 4 (21.1%) 0.752
DKA 40 (42.1%) 36 (47.4%) 4 (21.1%) 0.038
Group A, C-peptide level at 15th year < 0.05 nM/L; Group B, C-peptide level at 15th 
year ≥ 0.05 nM/L. DKA, diabetic ketoacidosis.
tially low, both gradually increased over time. The overall chan-
ges in weight SDS and BMI SDS between groups A and B were 
not significantly different from one another in the linear mixed-
model analysis. Pair-wise comparisons between the two groups 
at each time point, however, revealed significant differences 15 
yr after diagnosis (weight SDS, P = 0.012; BMI SDS, P = 0.044; 
Fig. 2). 
DISCUSSION
Some previous studies investigated the temporal variation in C-
peptide levels to understand the natural course of C-peptide 
levels in type 1 diabetes. In the Diabetes Prevention Trial-Type 
1 (DPT-1), sharp declines of stimulated C-peptide were observ-
ed during the six months prior to diagnosis (10, 11). This sug-
gests that a large amount of beta-cell function is commonly lost 
in the peri-diagnostic period and could explain the low initial 
C-peptide levels found in the present study (12). The level of C-
peptide secretion following diagnosis could be influenced by 
several factors, however, so the decline of C-peptide levels would 
not be expected to proceed uniformly (8, 9). In the present study, 
C-peptide secretion appeared to increase temporarily in the 
year following diagnosis, although the increase was not statisti-
cally significant. The trend of higher C-peptide levels in the first 
year might be a so-called “honeymoon” period of transient nor-
malization of beta-cell function caused by diligent care follow-
ing diagnosis (13). Serum C-peptide levels gradually decreased 
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after the first year, and the decrease was significant 5 to 10 yr af-
ter the diagnosis.
 We did not find any correlations between the variance of 
fasting C-peptide level and the variance of HbA1c level. The Di-
abetes Control and Complications Trial (DCCT), designed to 
compare intensive and conventional diabetes therapies, found 
that the intensive glucose-control group had lower HbA1c lev-
els and a slower decline in stimulated C-peptide levels after di-
agnosis (14, 15). Most of the subjects in the present study were 
treated with a conventional insulin regimen; therefore we could 
not confirm the effect of intensive therapy on residual beta-cell 
function or C-peptide levels.
 Many previous studies indicated that C-peptide slows the 
microvascular damage caused by the progression of type 1 dia-
betes (4-7). The capillary blood flow in the organs of type 1 dia-
betes patients could increase with C-peptide secretion or infu-
sion (16). The incidence of type 1 diabetes complications such 
as peripheral neuropathy, diabetic retinopathy, and albumin-
uria, however, showed no significant difference between pati-
ents with low and relatively higher C-peptide levels in the pres-
ent study. One previous study found that a fasting C-peptide 
level of at least 0.06 nM/L had a significant protective effect aga-
inst the development of microvascular complications (17). An-
other study showed that prolonged insufficient secretion of C-
peptide was associated with the development of microvascular 
complications (18). The correlation found in the present study 
between the elevated incidence of DKA and the decrement of 
C-peptide could be explained by the previously proven relation-
ship between hyperglycemia and beta-cell dysfunction (19-21): 
the incidence of DKA could mean lower beta-cell mass with ear-
lier depletion of C-peptide.
 The weight SDS and the BMI SDS of the patients with low C-
peptide levels increased gradually in our study. The weight SDS 
and BMI SDS of the patients with relatively preserved C-peptide 
levels, however, did not increase. Although the overall variances 
of weight change were not significantly different between the 
two groups in the linear mixed-model analysis, they were sig-
nificantly different 15 yr after diagnosis. Weight gain is known 
as one of the major adverse effects of insulin therapy (22, 23). 
The weight gain caused by insulin treatment in type 1 diabetes 
could interact with decreased beta-cell function, and it is a known 
factor increasing insulin resistance in type 1 diabetes (24, 25). It 
is unclear whether the C-peptide decrement or the weight gain 
is more influential in causing insulin resistance. It is known, how-
ever, that insulin resistance is strongly associated with other me-
tabolic complications such as hypertension, dyslipidemia, and 
atherosclerosis (26, 27). From this point of view, patients with 
type 1 diabetes who have preserved C-peptide secretion might 
gain beneficial effects on weight-gain-related complications af-
ter a long period of time.
 This study has several limitations. First, we had to exclude the 
autoimmune factors of diabetes such as islet-cell antibodies, 
insulin autoantibodies, and autoantibodies to glutamic-acid 
decarboxylase from the analysis because of inconsistent mea-
surements and a lack of data. Previous studies of autoimmune 
antibodies mainly focused on the onset of diabetes and not on 
the prognosis of type 1 diabetes (28, 29). Future studies of the 
effects of C-peptide on the progression of type 1 diabetes should 
include data for autoimmune antibodies. Second, our data in-
clude only fasting C-peptide concentrations without stimulated 
C-peptide levels. More accurate analysis of beta cell functions 
could be produced by comparing with the two types of data. 
Third, the number of patients in the relatively preserved C-pep-
tide group was only 19, and the duration of the follow-up peri-
od was not enough. Long-term, multi-center studies with more 
patients would likely provide more insights.
 In conclusion, we demonstrated that serum C-peptide levels 
significantly decreased 5 yr after diagnosis of type 1 diabetes. 
Patients whose beta-cell functions were preserved had fewer 
incidences of DKA, although we did not find significant effects 
on other complications of diabetes. Our results suggest that the 
declines in C-peptide levels and beta-cell function after diagno-
sis in type 1 diabetes are associated with changes of the body 
weight and BMI. 
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